{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:15:17Z","timestamp":1793837717058,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/mt.2016.67","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T07:21:35Z","timestamp":1459754495000},"page":"1323-1332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Kristian","family":"Taipale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Liikanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raita","family":"Heiskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Oksanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Gr\u00f6nberg-V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.67_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.67_bib2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.67_bib3","series-title":"Summary of opinion (initial authorisation): Imlygic","author":"EMA","year":"2015"},{"key":"10.1038\/mt.2016.67_bib4","series-title":"FDA Approves First-of-Its-Kind Product for the Treatment of Melanoma (press release)","year":"2015"},{"key":"10.1038\/mt.2016.67_bib5","doi-asserted-by":"crossref","first-page":"e28694","DOI":"10.4161\/onci.28694","article-title":"Trial Watch:: oncolytic viruses for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2016.67_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1089\/hum.2015.055","article-title":"Replication-competent viruses as cancer immunotherapeutics: emerging clinical data","volume":"26","author":"Zamarin","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.67_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2016.67_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.67_bib9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2016.67_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.67_bib11","doi-asserted-by":"crossref","first-page":"e989771","DOI":"10.4161\/2162402X.2014.989771","article-title":"Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy","volume":"4","author":"Liikanen","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2016.67_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mt.2015.143","article-title":"Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus","volume":"24","author":"Taipale","year":"2016","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/mt.2014.218","article-title":"Case\u2013control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors","volume":"23","author":"Kanerva","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib14","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1038\/mt.2016.67_bib16","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.67_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mt.2016.67_bib18","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.67_bib19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2016.67_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.67_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2016.67_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-1","article-title":"Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses","volume":"2","author":"Zloza","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1038\/mt.2016.67_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsb.2011.03.010","article-title":"How vaccinia virus has evolved to subvert the host immune response","volume":"175","author":"Bahar","year":"2011","journal-title":"J Struct Biol"},{"key":"10.1038\/mt.2016.67_bib24","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2016.67_bib25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/mt.2015.125","article-title":"Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues","volume":"23","author":"Koski","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib26","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.67_bib27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2016.67_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mt.2016.67_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/cgt.2013.49","article-title":"The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors","volume":"20","author":"Young","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2016.67_bib30","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2174\/138920112800958913","article-title":"Oncolytic viruses for induction of anti-tumor immunity","volume":"13","author":"Tong","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1038\/mt.2016.67_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4161\/onci.20172","article-title":"Oncolytic adenoviruses: a potent form of tumor immunovirotherapy","volume":"1","author":"Cerullo","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2016.67_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","article-title":"The liver as a lymphoid organ","volume":"27","author":"Crispe","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mt.2016.67_bib33","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1038\/mt.2016.67_bib34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","article-title":"Sex differences in autoimmune disease from a pathological perspective","volume":"173","author":"Fairweather","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1038\/mt.2016.67_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1038\/mt.2016.67_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"10.1038\/mt.2016.67_bib37","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2016.67_bib38","doi-asserted-by":"crossref","first-page":"727s","DOI":"10.1158\/1078-0432.CCR-06-1924","article-title":"Reversal of tumor-mediated immunosuppression","volume":"13","author":"Vieweg","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.67_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1038\/mt.2016.67_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ijgc-00009577-200201000-00002","article-title":"Immunology of the peritoneal cavity: relevance for host-tumor relation","volume":"12","author":"Melichar","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/mt.2016.67_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/08830185.2011.569902","article-title":"Peritoneal immune system in patients with advance epithelial ovarian cancer","volume":"30","author":"Wertel","year":"2011","journal-title":"Int Rev Immunol"},{"key":"10.1038\/mt.2016.67_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-4-30","article-title":"Monocyte\/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease","volume":"4","author":"Wang","year":"2006","journal-title":"J Transl Med"},{"key":"10.1038\/mt.2016.67_bib43","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.18632\/oncotarget.3453","article-title":"Characterization of tumor infiltrating natural killer cell subset","volume":"6","author":"Levi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2016.67_bib44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/10430340260185139","article-title":"Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy","volume":"13","author":"Hemminki","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.67_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2016.67_bib46","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2016.67_bib47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/s12885-015-1599-9","article-title":"Neutrophil count is associated with survival in localized prostate cancer","volume":"15","author":"Bahig","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1038\/mt.2016.67_bib48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1038\/mt.2016.67_bib49","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1158\/1078-0432.CCR-13-1471","article-title":"Oncolytic virotherapy trials\u2013letter","volume":"19","author":"Hemminki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2016.67_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mt.2011.230","article-title":"Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer","volume":"20","author":"Koski","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib51","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"Pesonen","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2016.67_bib52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib53","doi-asserted-by":"crossref","first-page":"e32871","DOI":"10.1371\/journal.pone.0032871","article-title":"SPECT\/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I","volume":"7","author":"Rajecki","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mt.2016.67_bib54","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib55","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"Liikanen","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.67_bib56","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1002\/ijc.28615","article-title":"In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders","volume":"134","author":"Hemminki","year":"2014","journal-title":"Int J Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616303641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:51:06Z","timestamp":1761501066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616303641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1525001616303641"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.67","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2016.67","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}